Metrics raised 1
- Astec FY27 revenue growth guidance raised to >20% (from prior lower, not specified)
Metrics cut 1
- Consolidated FY27 PBT growth guidance revised down to double-digit (from mid-teens)
Event Participants
Executives
4 Burjis Godrej, Sunil Kataria, S. Varadaraj, Arijit Mukherjee
Analysts
5 Abhijeet Akella, Arun, Hardik Solanki, Probal Sen, Vanshika Jain
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Consolidated Revenue | ₹2,852 crores | +10% YoY despite delayed monsoon and geopolitical inflationary pressures |
| Animal Nutrition Revenue | +12.6% YoY | Driven by robust demand, improved realization, and 15% growth in cattle feed volumes |
| Animal Nutrition Segment Results | +29% reported / +36% underlying | Benefited from strategic sourcing, operating leverage, and continued cost discipline |
| Oil Palm Revenue | +28.9% YoY | Supported by higher CPO and PKO realizations, increased sales volumes, and improved oil extraction efficiency |
| Oil Palm Segment Results | +14.4% YoY | FFB volumes flat against strong comparable (early monsoon last year) |
| Crop Care Revenue | -16.2% YoY | Significant delay in monsoon and slower kharif sowing hit cotton herbicide volumes; margin contracted |
| Dairy Revenue | +11.4% YoY | Led by healthy volume growth in value-added products; VAP salience rose from 42% to 49% |
| Godrej Foods Revenue | Broadly stable YoY | Planned Live bird volume reduction; branded volume +6%, Yummiez volume +22% |
| Astec LifeSciences EBITDA | Breakeven | vs EBITDA loss of ₹11 crores in Q1 FY26; margin expansion in enterprise and CDMO |
| Oil Extraction Ratio | 18.8% | vs 18.4% in Q1 FY26; improved extraction efficiency despite dry June |
| Working Capital | Improved significantly YoY | Supports objective of strengthening cash generation and enhancing RoCE |
Geographic & Segment Commentary
Animal Nutrition: Delivered strong quarter with revenue growth of 12.6%, cattle feed volumes up 15%, and overall segment volumes up 7%. Segment results grew 29% reported / 36% underlying, reflecting strategic sourcing, operating leverage, and cost discipline. Poultry is under planned de-growth in select geographies, while cattle, fish, and swine feed are focus growth areas (fish feed volumes +20%+).
Oil Palm: Revenue grew 28.9% with segment results up 14.4%, supported by higher CPO/PKO realizations and improved OER of 18.8% (vs 18.4% YoY). FFB volumes held flat against a strong comparable that benefited from early monsoon onset, attributed to extension work and the demographic dividend of maturing plantations. No structural margin concern; timing/seasonality viewed as principal factor.
Crop Care (Standalone): Revenue declined 16.2% due to one of the driest Junes on record (40% rainfall deficit), impacting cotton herbicide volumes and margins. Portfolio diversification gaining traction—Ashitaka (maize herbicide) and Takai (paddy insecticide) scaled up with encouraging market acceptance, together contributing 18–20% of Q1 sales; Ghassnash (soybean herbicide) launched. EBIT margin guidance of ~26–27% maintained.
Astec LifeSciences: Sustained operational recovery, at EBITDA breakeven vs ₹11 crore loss in Q1 FY26. Revenue moderately lower due to product mix change; margin expansion driven by turnaround initiatives. Revenue growth guidance raised to >20% for FY27 with CDMO salience of ~50–52%; some demand shift from H1 to H2.
Dairy (CDPL): Revenue grew 11.4% with volumes up 8%—first strong top-line recovery in several quarters. Value-added salience rose from 42% to 49%. Profitability impacted by elevated milk procurement prices (industry-wide availability constraints) and packaging inflation from Middle East geopolitical tensions; 70% pricing passed to market. Route-to-market transformation (18–20 month exercise) to be piloted shortly.
Godrej Foods: Revenue broadly stable with planned Live bird de-growth of 15–20% per year. Branded B2C business (Yummiez + Real Good) grew 28% volume / ~20% value, now 32% of total business. New products launched—frozen momos, Crispy Bites, sauces; frozen chicken category creation underway. Profitability affected by higher input costs and geopolitical inflation.
Bangladesh JV (ACI Godrej Agrovet): Returned to broad-based double-digit growth in volume, revenue, and PBT, supported by operating leverage and new leadership initiatives.
Company-Specific & Strategic Commentary
Oil Palm Downstream Integration: Launched India's first integrated palm oil complex in Khammam (nursery + CPO mill); specialty fats refinery slated for end-August/early-September. Expected to add ~200 bps to overall EBITDA when fully scaled, transforming business from upstream to integrated value-added player. CapEx of ₹300–350 crores covers these investments, all passing a 16–18% IRR filter.
Crop Care Diversification: Strategic de-risking from cotton herbicide concentration via new product launches—Ashitaka, Takai, Ghashnash—targeting maize, paddy, and soybean. Together contributing 18–20% of Q1 sales already; goal is a multi-crop, multi-product portfolio over 5 years.
Godrej Foods B2C Transformation: Strategic pivot to a protein-forward branded foods company. Live bird to be reduced to a marginal back-end supply chain role (₹20–30 crores over 5 years); B2C (Yummiez + Real Good) growing 20%+ each quarter and targeted to reach 65–70% of company revenue by end of long-range plan.
Dairy Route-to-Market Transformation: Consolidating geographies, reconstituting route-to-market under new CEO Gaurav; pilot starting next month, full rollout over 18–20 months. Doubling down on premium value-added products to improve contribution margins over 18–24 months.
Area Expansion & Demographic Dividend: Oil palm area expansion on track—17,000 hectares added last year, ahead of internal plans in Q1; targeted expansion from ~80,000 to ~150,000 hectares, with Telangana and Northeast as new geographies. ~50% of plantations are in juvenile stage (0–4 years), providing built-in volume growth as trees mature.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Consolidated PBT Growth | Double-digit for FY27 (revised from mid-teens) | Confident in double-digit; exact range to be provided by end of Q2 after crop care season assessment |
| Astec Revenue Growth | >20% for FY27 | Q1 dip of ~8–9% to be recovered in coming quarters; H2 weighted |
| Astec CDMO Salience | ~50–52% of revenue | Customers shifting orders from H1 to H2; orders confirmed and discussions ongoing |
| Animal Feed EBIT/ton | ₹2,050–2,150 range maintained | Premiumization, geography expansion, and NPD pipeline as structural drivers |
| Oil Palm FFB Volume Growth | High single digit to early double digit (4–5 year LRP horizon) | Area expansion, demographic dividend, new geographies; conservative given weather variability |
| Oil Palm Financial Impact | ~200 bps EBITDA addition from specialty fats when fully scaled | Downstream integration into B2B food ingredients (chocolate, bakery) |
| Capex | ₹300–350 crores | Covers integrated palm complex, specialty fats, and ongoing projects; 16–18% IRR filter |
| Crop Care Assessment | Call by end of September | Depends on cotton herbicide season; July growth better YoY; multiple positives in H2 |
| Dairy | Milk price pressure to persist 2–3 quarters | Packaging inflation from Middle East war to normalize by August; ~70% pricing passed to market |
Risks & Constraints
| Risk | Context |
|---|---|
| Erratic Monsoon / Weather | One of the driest Junes on record (40% rainfall deficit) hit crop care volumes and profitability in Q1; cotton herbicide season assessment pending September-end. Management sees multiple positives in H2—new products, firmer chili prices, normal October–November expectations—but full-year recovery remains uncertain. |
| Elevated Milk Procurement Prices | Industry-wide milk availability constraints have inflated procurement prices for four quarters; expected to persist for 2–3 more quarters. Management passing ~70% of pricing to market, balancing consumer acquisition; cost initiatives and RTM transformation are key mitigation levers. |
| Geopolitical Inflation (Packaging/LPG) | Middle East war drove LPG and packaging cost inflation impacting dairy and foods profitability; packaging normalization expected by August as inventories clear, but residual Q2 impact likely. |
| CDMO Demand Timing Shift | Customers shifting demand from H1 to H2; orders confirmed but revenue recognition weighted to second half, creating intra-year variability. |
| Feed Commodity Price Volatility | Maize prices increased sharply; management passed 60–70% to market and navigated better than industry via strategic sourcing, but the benefit may be partly non-structural. |
Q&A Highlights
Oil Palm Growth & Downstream Integration
- Question: What is the 3–5 year volume outlook, value addition metrics, and EBITDA trajectory for oil palm? (Abhijeet Akella)
- Answer: FFB volume growth of high single digit to early double digit on a CAGR basis—conservative given weather variability. Driven by area expansion (80k to 150k hectares target, Telangana/Northeast), ~50% of plantations in juvenile stage, and best-in-class OERs. Khammam integrated complex (nursery + CPO mill) rolled out; specialty fats refinery in end-August/September. Downstream business expected to add ~200 bps to overall EBITDA when fully scaled. CapEx of ₹300–350 crores covers all this, passing 16–18% IRR filter. (Sunil Kataria)
Crop Care Recovery & Consolidated Guidance
- Question: Given the soft start, what can we expect for crop care and Astec this year? Is the mid-teens consolidated PBT growth still achievable? (Abhijeet Akella)
- Answer: June was one of the driest on record (40% deficit), impacting sowing and herbicide application. July is tracking better YoY. A full recovery assessment will be possible by end-September after the cotton herbicide season. Positives include softer base, normal October–November expectations for Gracia and Combined (chili/grape products), firm chili prices, and new product rollouts (Ashitaka, Takai, Ghashnash). Astec guidance raised to >20% revenue growth for FY27 with CDMO salience of 50–52%. Consolidated PBT: confident of double-digit, exact range by end of Q2. (Sunil Kataria, Arijit Mukherjee)
Godrej Foods Strategy Clarification
- Question: What's driving the relative underperformance in dairy and frozen foods, and has the environment changed in Q2? (Probal Sen)
- Answer: Godrej Foods is actually performing exceptionally well—the business needs to be delayered. Live bird is undergoing planned de-growth of 15–20% annually (targeting near zero in 5 years, becoming marginal back-end supply chain). The branded B2C business (Yummiez + Real Good) is growing 28% volume / ~20% value this quarter, at 32% of total revenue, and should reach 65–70% of company revenue by end of LRP. New NPDs include frozen momos (chicken, chicken cheese, veg in 3–4 months), Crispy Bites, sauces, and a frozen chicken category creation play. The business is in an investment phase, typical of scaling FMCG companies. (Sunil Kataria)
Dairy Transformation & Margin Outlook
- Question: How do you see the dairy business recovering from Q1 pressures? (Probal Sen)
- Answer: CDPL volumes grew 8% (first strong top-line recovery in quarters) with 11.5% value growth. Two pressures: (1) one-off packaging/LPG inflation from the Middle East war—should normalize by August as inventories clear; (2) milk procurement prices elevated for four quarters, expected to persist 2–3 more quarters, with ~70% passed to market. Strategic response: route-to-market transformation (18–20 months, pilot next month), doubling down on value-added portfolio premiumization, and cost initiatives. Focus is driving value-added growth profitably. (Sunil Kataria)
Animal Nutrition Margins & Maize Prices
- Question: How is the huge maize price increase impacting volumes and margins? (Vanshika Jain)
- Answer: Passed ~60–70% of commodity inflation to market. Overall segment volumes grew 7% with cattle feed up 15%; fish feed up over 20%. Poultry is under planned geographic de-growth—conscious choices to exit unprofitable geographies/segments. EBIT/ton guidance maintained at ₹2,050–2,150, delivered at the higher end this quarter. Premium feed adoption is being supported by high milk procurement prices, as farmers upgrade to productivity-enhancing branded feed. Bangladesh JV (ACI Godrej) is on a turnaround with double-digit volume/value growth in Q1. (Sunil Kataria)
Oil Palm Margins & OER Clarification
- Question: Realizations are up 18% and OER improved, yet EBIT margin fell from 19% to 17%—is higher CPO being passed to farmers? (Vanshika Jain, Arun)
- Answer: The margin dip is due to formula-based pricing changes from government intervention within the quarter and flat FFB volumes (seasonal—last year's early monsoon vs this year's driest June). OER improved to 18.8% from 18.4%. Peak Q2/Q3 seasons, FFB volume growth, scale efficiencies in factories, and specialty fats ramp-up in H2 should restore margins. No structural issue. (Sunil Kataria)
Crop Care Competitiveness vs Peers
- Question: Peers have outgrown the company despite the same environment—is this an execution issue? (Hardik Solanki)
- Answer: Segment mix matters—the company has historical concentration in cotton herbicide, which was disproportionately hit by the dry June. Same-segment competitive intelligence shows no market share loss. The diversification drive (Ashitaka, Takai, Ghashnash) is precisely to build a multi-crop, multi-product portfolio over the LRP and reduce this dependence. (Sunil Kataria)
Crop Care Margins on New Products
- Question: What margins can we expect from Ashitaka, Takai, and Ghashnash vs Hitweed? (Arun)
- Answer: Margins will be lower than Hitweed (in-licensed vs in-house products), but still healthy—these are not generic products. Scale benefits and backend efficiency gains will improve margins over time. Business-level EBIT margin of ~26–27% is still attainable despite the tough year. (Sunil Kataria)
Key Takeaway
Godrej Agrovet delivered consolidated revenue of ₹2,852 crores (+10% YoY) in Q1 FY27, despite a historically dry June and geopolitical cost inflation. Animal nutrition and oil palm drove the quarter—animal nutrition grew revenue 12.6% with segment results up 29%, while oil palm grew revenue 28.9% with OER improving to 18.8%. Crop care was the drag (-16.2% revenue) due to the delayed monsoon, though new products (Ashitaka, Takai, Ghashnash) contributed 18–20% of segment sales. Management repositioned the portfolio strategically: oil palm is integrating downstream (specialty fats refinery, Khammam complex) expected to add ~200 bps to EBITDA; Godrej Foods is pivoting aggressively to B2C with Yummiez growing 28% volume; dairy is undergoing an 18–20 month route-to-market transformation. Consolidated PBT guidance was revised to double-digit (from mid-teens) pending September's crop care assessment; Astec guidance was raised to >20% revenue growth. Key watch points: monsoon recovery in H2, milk procurement price persistence (2–3 quarters), and live bird de-growth execution.